# Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients

> **NCT06308718** · — · TERMINATED · sponsor: **Forge Biologics, Inc** · enrollment: 2 (actual)

## Conditions studied

- Krabbe Disease

## Interventions

- **BIOLOGICAL:** FBX-101

## Key facts

- **NCT ID:** NCT06308718
- **Lead sponsor:** Forge Biologics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2024-08-06
- **Primary completion:** 2025-04-10
- **Final completion:** 2025-04-11
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** The FBX-101 clinical program has been discontinued by Forge Biologics
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06308718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06308718, "Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06308718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*